Trajan Group (ASX:TRJ) has signaled a turnaround in its second quarter, maintaining its full-year guidance despite a challenging start to FY26.
The global analytical science specialist reported a 3.8% increase in group net revenue for the first half, reaching $84.1 million, up from $81 million in the previous corresponding period.
While the first quarter was hampered by a temporary downturn in Capital Equipment demand, the company achieved record quarterly revenue of $45.4 million in Q2.
The momentum was bolstered by a $2.8 million expansion in the Capital Equipment order book, highlighting a swift recovery in workflow automation sales.
Although H1 normalised EBITDA landed at $5 million—impacted by $1.3 million in non-cash FX revaluations and $0.8 million in freight and US tariff timing—the quarterly trajectory showed a dramatic improvement, surging from $0.5 million in Q1 to $4.5 million in Q2.
To safeguard second-half margins, Trajan is accelerating its "Project Neptune" cost-out initiative and has implemented strategic pricing actions effective January 2026.
The measures are expected to deliver over $2.1 million in combined benefits.
Management reaffirmed its FY26 revenue guidance of $170 million to $180 million, supported by a strengthening pipeline in the pharmaceutical and food sectors.
At the time of reporting, Trajan Group's share price was $0.68.